Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label BCX7353 safety study in hereditary angioedema
NL-OMON48865Phase 2Active, not recruiting
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of berotralstat in hereditary angioedema (HAE) (2 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Long-term safety and tolerability of daily oral BCX7353. Started Jan 2019; status: active, not recruiting.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON48865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48865.